Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a promising company with a strong pipeline focused on novel gene and cell therapies and vaccines. Their modifier gene therapy platform has shown impressive results in treating retinal diseases, and their upcoming Phase 3 study for OCU410 is expected to show even greater efficacy. Additionally, the company has a clean safety profile, and if successful, their one-and-done administration could lead to high adoption rates. While there are financing risks and challenges in the biotech industry, Ocugen's potential for future revenue and partnerships make us confident in our increased price target of $10.00 per share.

Bears say

Ocugen is a biopharmaceutical company with a focused pipeline targeting retinal diseases and a COVID-19 vaccine. While they have seen recent success in their Phase 2 ArMaDa study, there is no guarantee of continued success and regulatory approvals for their therapies. Additionally, there is potential for high costs in legal expenses and challenges with intellectual property, making it a risky investment opportunity.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.